Huvepharma Sea (Pune) Profile
Key Indicators
- Authorised Capital ₹ 1.30 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.30 Cr
as on 23-10-2024
- Company Age 15 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.05 Cr
as on 23-10-2024
- Satisfied Charges ₹ 12.00 Cr
as on 23-10-2024
- Revenue 3.62%
(FY 2023)
- Profit -5.03%
(FY 2023)
- Ebitda -4.35%
(FY 2023)
- Net Worth 30.55%
(FY 2023)
- Total Assets 12.19%
(FY 2023)
About Huvepharma Sea (Pune)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.30 Cr and a paid-up capital of Rs 1.30 Cr.
The company currently has active open charges totaling ₹21.05 Cr. The company has closed loans amounting to ₹12.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Om Singh, Kiril Domuschiev, and Viktor Prodanov serve as directors at the Company.
- CIN/LLPIN
U15122PN2009FTC135083
- Company No.
135083
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
30 Nov 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Huvepharma Sea (Pune)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Om Singh  | Managing Director | 30-Nov-2009 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiril Domuschiev  | Director | 30-Nov-2009 | Current |
| Viktor Prodanov | Director | 11-Nov-2011 | Current |
Financial Performance and Corporate Structure Insights of Huvepharma Sea (Pune).
Huvepharma Sea (Pune) Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.62% increase. The company also saw a slight decrease in profitability, with a 5.03% decrease in profit. The company's net worth Soared by an impressive increase of 30.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Huvepharma Sea (Pune)?
In 2023, Huvepharma Sea (Pune) had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Huvepharma Biosciences (India) Private LimitedActive 2 years 2 monthsOm Singh and Viktor Prodanov are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 31 Aug 2021 | ₹1.05 Cr | Open |
Citi Bank N.A. Creation Date: 26 Nov 2014 | ₹20.00 Cr | Open |
Citi Bank N.A. Creation Date: 28 May 2018 | ₹5.00 Cr | Satisfied |
How Many Employees Work at Huvepharma Sea (Pune)?
Huvepharma Sea (Pune) has a workforce of 61 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Huvepharma Sea (Pune), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Huvepharma Sea (Pune)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
